Physician
Alliance Cancer Specialists P.C.
Alliance Cancer Specialists P.C. was paid $1.24M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 30% of everything it billed.
33Billing provider infoALLIANCE CANCER SPECIALISTS P.C.
SELLERSVILLE, PA 18960
SELLERSVILLE, PA 18960
33aNPI1487923686assigned 12/19/2011
33bProvider typeRadiation Oncology Physician
28Total paid$1.24M
24GClaims45,158
24DCodes billed40
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Radiation Oncology Physician providers in Pennsylvania
Rank by total paid#2 of 23
Median peer was paid$3K
This provider vs. median386×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52 | $628.62 | |
| 2020 | 1,402 | $25K | |
| 2021 | 6,931 | $365K | |
| 2022 | 12,278 | $302K | |
| 2023 | 14,170 | $318K | |
| 2024incomplete | 10,325 | $227K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 30% | 8,127 | 7,088 | $375K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 6,648 | 6,122 | $227K |
| J9271 | Injection, pembrolizumab, 1 mg | 15% | 587 | 452 | $184K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 11% | 1,697 | 1,000 | $140K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 6.6% | 2,608 | 1,528 | $81K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 6.5% | 1,347 | 759 | $80K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.7% | 9,562 | 7,192 | $46K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.5% | 180 | 148 | $18K |
| J0897 | Injection, denosumab, 1 mg | 1.4% | 496 | 474 | $17K |
| J1756 | Injection, iron sucrose, 1 mg | 1.2% | 3,559 | 1,384 | $15K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 565 | 313 | $9K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | <1% | 169 | 115 | $8K |
28 more codes
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 190 | $7K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 316 | $7K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,984 | $5K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 226 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 78 | $3K |
| 94010 | <1% | 710 | $2K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 267 | $2K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 45 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 188 | $1K |
| 96367 | <1% | 56 | $986.31 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 39 | $746.24 |
| 94726 | <1% | 107 | $605.25 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 340 | $587.52 |
| 94729 | <1% | 102 | $465.72 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 32 | $417.66 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 31 | $390.18 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,176 | $385.33 |
| 96160 | <1% | 55 | $92.67 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,218 | $51.87 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 0% | 336 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 385 | $0.00 |
| J0185 | Injection, aprepitant, 1 mg | 0% | 205 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 26 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 237 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 93 | $0.00 |
| J1437 | Injection, ferric derisomaltose, 10 mg | 0% | 65 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 79 | $0.00 |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTERZIAN, ALLEN (PRESIDENT)